A recent study published in The Lancet Oncology shows how exemestane (Aromasin), a drug that prevents the development of breast cancer in postmenopausal women, may significantly worsen age-related bone loss. As an aromatase inhibitor, exemestane works by blocking the synthesis of estrogen, slowing down the growth of cancers that have estrogen receptors...
More...
Threaded Mode